Twice in One Month

From Drug and Device Law
April 26, 2013 - 12:39pm
            We hadn’t blogged about the Biomaterials Access Assurance Act (“BAAA”), 21 U.S.C. §§1601-1606, since 2008 (see post), and now we are posting about it for a second time this month.  Maybe we should hashtag BAAA and see if we can start a Google trend.  Maybe not.              Our prior posts focused on the BAAA’s procedural device that allows a biomaterial supplier to be dismissed upon a showing that the supplier is not a "manufacturer" of the final implant, is not a "seller" of the final implant, and did not fail "to meet applicable contractual requirements" relating to the raw material. 21 U.S.C. §1604(a).  While this latest case, Sadler v. Advanced Bionics, LLC, 2013 U.S. Dist. LEXIS 54697 (W.D. Ken. Apr. 16, 2013), deals with that as well, it also addresses the preemptive effect of the BAAA.  This is also a case where the claim against the biomaterial supplier was brought by the medical device manufacturer, the defendant, rather than the plaintiff -- which is why the court got the preemption issue.               It is important to the preemption discussion to know that Kentucky has adopted comparative fault/several liability for all tort actions, including products liability.  Id. at *7-8.   “In all tort actions, including products liabil...

Continue reading this article »



POPULAR PHARMA NEWS & ARTICLES

PHARMA NEWS, ARTICLES & UPDATES


More Pharma News & Articles »

Pharma Description

The Pharmaceutical industry develops, produces, and markets drugs or pharmaceuticals licensed for use as medications.

Pharma DRILLDOWN

American Dental Association  Bidvest  Raeburn  Lonza  FDA-required  World Data  Reckitt Benckiser  SEC Form  Motrin  Charles Grassley  Andrew Witty  Witty  Health Benefits  Pleas  Glenmark  Indian IP  Psychiatric  Multichannel Marketing  PLIVA  Submissions  Medical Devices  Primary Care  Vytorin  Kenneth Frazier  Diovan  Healthcare Informatics  Petition  Flash-based  Eisai  Pennsylvania Superior  Medicinal Products  Human Use  European Medicines Agency  Bristol-Myers  Actelion  Payment Advisory Board  Fosamax ONJ  Alnylam  Drug Administration Safety  Permanent  Zilmax-fed  IMS Health  The Lancet  Bausch  Lomb  Tim Anderson  CAFO  Lanham Act  DOTW  CEO Brent Saunders  ViroPharma  Merial  FOTF  Unfair  CEO Jeremy Levin  Flu  2013*Drugs  Fluoride Action Network  Transparency  Lemtrada  FierceBiotech  Fast Fred Hassan  Nutrients  Found  Not Robots  AmerisourceBergen  Expo West  Payers  Managed  Endo Health Solutions  Valeant Pharmaceuticals  Endo  Series B  Vascepa  Aredia-Zometa  Hematology  SmithKline  Safe  GRAS  Lucy  Charlie Brown  ABPI  CEO Joe Jimenez  Statins  Interactive Data  Electronic  Premarket Approval  CV  Twombly  Beecham  PharmaTimes  Timothy  Soriot  Moderna  Inspector General  Cerner  Jimenez  Elsevier Policy  Enforcement  Happens 

Pharma Blogroll

.Google Health   Alison-bass   Articles.mercola   Biopharmatoday   Biotechblog   Brodyhooked   Businessethicsblog   Cenblog   Druganddevicelaw   Drugchannels   Elsevierbi   Evidenceinmedicine   Eyeonfda   Fairwarning   Fdamatters   Fiercepharma   Hcrenewal   Health Sciences Institute   Health-watched   Healthiertalk   Healthnewsreview   Invivoblog   Ivanho   Medadnews   Nashhealthpolicy   nutraingredients   Nutraingredients-usa   Orangebookblog   Patentbaristas   Patents4life   Pfizer   Pharmalive   Pharmalot.com   Pharmamkting   Pharmaphorum   Pipeline.corante   prescriptionaccess   Researchethicsblog   Retraction-watch   Shearlingsplowed   Social.eyeforpharma   Spicyipindia   Worldofdtcmarketing